Mr. James Howard-Tripp reports
GENENEWS ANNOUNCES RESULTS OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS
GeneNews Ltd.'s shareholders voted in favour of all items of business, including the election of all nominee directors listed in the company's management information circular, dated May 15, 2019, at its annual and special meeting of shareholders held on June 19, 2019.
The results of the vote for the election of directors are set out in the attached table.
Nominee Votes for Votes withheld
James Howard-Tripp 96.86% 3.14%
Rory Riggs 99.84% 0.16%
Garth MacRae 99.85% 0.15%
Harry Glorikian 99.80% 0.20%
Thomas D. Stewart Jr. 99.78% 0.22%
GeneNews further announces that shareholders representing approximately 99.93 per cent of votes cast at the meeting, by proxy or in person, approved a special resolution authorizing the company to amend its articles to change its name to StageZero Life Sciences Ltd. The effective date of the name change will be the date of issuance of a certificate of amendment by the director under the Business Corporations Act (Ontario) upon filing by the company of articles of amendment. The company intends to file articles of amendment for the name change later today.
"The name change to StageZero Life Sciences reflects the company's dedication to finding cancer, as well as multiple diseases in the earliest possible stages (stage 0) through whole blood," says James R. Howard-Tripp, chairman and chief executive officer of GeneNews. "While our focus remains on commercializing advanced diagnostics for early cancer detection, our primary mission is to finalize the validation of our next-generation test, Aristotle, a blood test for simultaneously screening for 10 specific cancers from a single sample of blood. We will also explore the application of Aristotle to multiple disease states in neurology, gastroenterology, cardiology and autoimmune disorders."
In addition to the election of directors and the name change, shareholders voted in favour of the following matters:
- Appointment of BDO Canada LLP as auditor of the company;
- Renewal of the company's stock option plan;
- Approval of the company's upcoming unit financing;
- Approval of a consolidation of the company's common shares.
More specific details of the matters approved at the meeting are set forth in the circular and posted on SEDAR. Voting results are released in accordance with the Toronto Stock Exchange requirements. Detailed voting results for the meeting are also available on SEDAR.
The company will have a new website. This name change will also apply to the company's United States lab, Innovative Diagnostic Laboratory.
In addition to the name change, the company will change its ticker symbol on the Toronto Stock Exchange to SZLS. The intended date for the activation of the new ticker is on or about June 26, 2019. Until then, the company's stock will continue to trade under the existing GEN ticker symbol.
About GeneNews Ltd.
GeneNews is dedicated to the early detection of cancer and multiple disease states through whole blood. Its next-generation test, Aristotle, is a multicancer panel for simultaneously screening for 10 cancers from a single sample of blood, with high sensitivity and specificity for each cancer. Aristotle is built on the company's proven and proprietary Sentinel Principle technology platform, which was validated on 10,000 patients and used to develop the first liquid biopsy for colorectal cancer. Further validation of the Aristotle test is currently under way.
We seek Safe Harbor.
© 2019 Canjex Publishing Ltd. All rights reserved.